Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 243 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Karagiannis, Asterios  [Clear All Filters]
2012
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Lipid lowering agents and the endothelium: an update after 4 years.. Curr Vasc Pharmacol. 10(1), 33-41.
Athyros, V. G., Elisaf M. S., Alexandrides T., Achimastos A., Ganotakis E., Bilianou E., et al. (2012).  Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.. Angiology. 63(5), 358-66.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome.. Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
Kostapanos, M. S., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.. Dig Dis Sci. 57(4), 1109.
Tziomalos, K., Athyros V. G., & Karagiannis A. (2012).  Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options.. Curr Vasc Pharmacol. 10(2), 162-72.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.. Am J Cardiol. 110(5), 763.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'.. Clin Cardiol. 35(5), 315; author reply 316-7.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Should raising high-density lipoprotein cholesterol be a matter of debate?. J Cardiovasc Med (Hagerstown). 13(4), 254-9.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial.. J Hepatol. 57(2), 476.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Stage of chronic kidney disease and severity of coronary heart disease manifestation.. Expert Opin Pharmacother. 13(4), 457-60.
Kostapanos, M. S., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Therapeutic options for statin-intolerant patients.. Curr Med Res Opin. 28(3), 345-9.
Mitsiou, E. K., Athyros V. G., Karagiannis A., & Mikhailidis D. I. (2012).  Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?. Open Cardiovasc Med J. 6, 28-32.
Katsiki, N., Koumaras C., Athyros V. G., & Karagiannis A. (2012).  Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk.. Angiology. 63(1), 9-11.
2011
Katsiki, N., Mikhailidis D. P., Athyros V. G., & Karagiannis A. (2011).  Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance.. Circ J. 75(8), 2027; author reply 2028.
Athyros, V. G., Karagiannis A., Ganotakis E. S., Paletas K., Nicolaou V., Bacharoudis G., et al. (2011).  Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.. Curr Med Res Opin. 27(8), 1659-68.
Stavrinou, E., Koumaras C., Gossios T. D., Tziomalos K., Athyros V. G., & Karagiannis A. (2011).  Atherosclerotic renal artery stenosis: an update on diagnosis and management.. Curr Vasc Pharmacol. 9(4), 465-70.
Pagourelias, E. D., Zorou P. G., Tsaligopoulos M., Athyros V. G., Karagiannis A., & Efthimiadis G. K. (2011).  Carbon dioxide balneotherapy and cardiovascular disease.. Int J Biometeorol. 55(5), 657-63.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Current treatment for nonalcoholic fatty liver disease.. Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.. Open Cardiovasc Med J. 5, 24-34.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.. Open Cardiovasc Med J. 5, 85-9.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Ezetimibe and low density lipoprotein subfractions: an ongoing debate.. Curr Med Res Opin. 27(3), 693-5.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?. Curr Vasc Pharmacol. 9(6), 698-705.
Anagnostis, P., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Impact of statins on glucose metabolism--a matter of debate.. Am J Cardiol. 107(12), 1866.
Athyros, V. G., Hatzitolios A. I., Karagiannis A., Savopoulos C., Katsiki N., Tziomalos K., et al. (2011).  IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.. Arch Med Sci. 7(6), 984-92.
Athyros, V. G., Katsiki N., Tziomalos K., & Karagiannis A. (2011).  Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. Open Cardiovasc Med J. 5, 226-30.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές